Enantiomerically pure phosphoindoles as HIV inhibitors

Details Enantiomerically pure phosphoindoles as HIV inhibitors Enantiomerically pure phosphoindoles as HIV inhibitors

2011-06-14

2011-06-14

Shiao, Rei-tsang (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S415000, C548S492000

Reexamination Certificate

active

07960428

ABSTRACT:
3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.

REFERENCES:
patent: 4866084 (1989-09-01), Gunasekera et al.
patent: 5124327 (1992-06-01), Greenlee et al.
patent: 5424329 (1995-06-01), Boschelli et al.
patent: 5489685 (1996-02-01), Houpis et al.
patent: 5527819 (1996-06-01), Williams et al.
patent: 5565446 (1996-10-01), Boschelli et al.
patent: 5703069 (1997-12-01), Connor et al.
patent: 5830894 (1998-11-01), Pevear et al.
patent: 5852011 (1998-12-01), Matsunaga et al.
patent: 5929114 (1999-07-01), Domagala et al.
patent: 5935982 (1999-08-01), Dykstra et al.
patent: 5945440 (1999-08-01), Kleinschroth et al.
patent: 5981525 (1999-11-01), Farina et al.
patent: 6017903 (2000-01-01), Slusher et al.
patent: 6025345 (2000-02-01), Jackson et al.
patent: 6025390 (2000-02-01), Farina et al.
patent: 6297270 (2001-10-01), Beller et al.
patent: 6506787 (2003-01-01), Fujishita et al.
patent: 6710068 (2004-03-01), La Colla et al.
patent: 6716605 (2004-04-01), Fujishita et al.
patent: 6825201 (2004-11-01), Wang et al.
patent: 6900206 (2005-05-01), Kadow et al.
patent: 7534809 (2009-05-01), Storer et al.
patent: 2002/0019434 (2002-02-01), Fujishita et al.
patent: 2003/0096825 (2003-05-01), Wang et al.
patent: 2003/0236277 (2003-12-01), Kadow et al.
patent: 2004/0006090 (2004-01-01), Kadow et al.
patent: 2004/0063746 (2004-04-01), Regueiro-Ren et al.
patent: 2006/0074054 (2006-04-01), Storer et al.
patent: 2009/0163444 (2009-06-01), Storer et al.
patent: 1799696 (2008-11-01), None
patent: WO 94/19321 (1994-09-01), None
patent: WO 96/29077 (1996-09-01), None
patent: WO 97/48399 (1997-12-01), None
patent: WO 97/48400 (1997-12-01), None
patent: WO 97/48409 (1997-12-01), None
patent: WO 98/13046 (1998-04-01), None
patent: WO 98/38332 (1998-09-01), None
patent: WO 98/53812 (1998-12-01), None
patent: WO 99/52915 (1999-10-01), None
patent: WO 01/02388 (2001-01-01), None
patent: WO 03/068221 (2003-08-01), None
patent: WO 03/090690 (2003-11-01), None
patent: WO 03/090691 (2003-11-01), None
patent: WO 03/091264 (2003-11-01), None
patent: WO 2004/014364 (2004-02-01), None
patent: WO 2006/054182 (2006-05-01), None
patent: WO 2008/042240 (2008-04-01), None
Alexandre et al., “Synthesis and Antiviral Activity of Phospho-Indoles as Novel NNRTI with Potent Anti-HIV Activity and Enhanced Barrier to Resistance,” Poster presented at ASMC07, St. Petersburg, Russia (Aug. 28-31, 2007).
Alexandre et al., “IDX 12899; A Novel and Highly Potent anti-HIV Non-Nucleosidic-Reverse-Transcriptase-Inhibitor with Enhanced Barrier to Resistance Profile,” Poster 21 presented at 14thSCI-RSC Medicinal Chemistry Symposium, Cambridge, UK (Sep. 23-26, 2007).
Aoyagi et al., “Studies on Chromogenic and Fluorogenic Substrates for Detection of Enzymatic Activities,” J. Fac. Eng. Chiba Univ., 26(49):185-191 (1974).
Artico et al., “2-Sulfonyl-4-Chloroanilino Moiety: A Potent Pharmacophore for the Anti-Human Immunodeficiency Virus Type 1 Activity of Pyrrolyl Aryl Sulfones,” J. Med. Che., 39:522-530 (1996).
Artico et al., “1-Arylsulfonyl-3-(α-hydroxybenzyl)-1H-Pyrroles, a Novel Class of Anti-HIV-1 Reverse Transcriptase Inhibitors,” Bioorganic & Med. Chem. Letters 7:1931-1936 (1997).
Artico et al., “Strucure-Based Design, Synthesis, and Biological Evaluation of Novel Pyrrolyl Aryl Sulfones: HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors Active at Nanomolar Concentrations,” J. Med. Chem., 43:1886-1891 (2000).
Baba et al., “Highly Potent and Selective Inhibition of HIV-1 Replication by 6-Phenylthiouracil Derivatives,” Antiviral Res., 17:245-264 (1992).
Balzarini et al., “2′5′-Bis-O-(tert-Butyldimethylsilyl)-3′-Spiro5″-(4″-Amino-1″,2″-Oxathiole-2″,2″-Dioxide) Pyrimidine (TSAO) Nucleoside Analogues: Highly Selective Inhibitors of Human Immunodeficiency Virus Type 1 that are Targeted at the Viral Reverse Transcriptase,” PNAS, 89:4392-4396 (1992).
Beilstein Registry No. 284968, Chemical Name “di-indol-3-yl-phosphinic acid,” Beilstein Entry Date: Jun. 27, 1988.
Bell et al., “Phenethylthiazolethiourea (PETT) Compounds, a New Class of HIV-1 Reverse Transcriptase Inhibitors. 1. Synthesis and Basic Structure-Activity Relationship Studies of PETT Analogs,” J. Med. Chem., 38:4929-4936 (1995).
Cantrell et al., “Phenethylthiazolylthiourea (PETT) Compounds as a New Class of HIV-1 Reverse Transcriptase Inhibitors. 2. Synthesis and Further Structure-Activity Relationship Studies of PETT Analogs,” J. Med. Chem., 39:4261-4274 (1996).
Chen et al., “Synthesis of Indoles via a Palladium-Catalyzed Annulation between Iodoanilines and Ketones,” J. Org. Chem., 62(9):2676-2677 (1997).
Danel et al., “Synthesis of Potent Anti-HIV-1 Activity of Novel 6-Benzyluracil Analogues of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine,” J. Med. Chem., 39:2427-2431 (1996).
Danel et al., “Anti-HIV Active Naphthyl Analogues of HEPT and DABO,” Acta Chemica Scandinavica, 51:426-430 (1997).
DeClercq, “HIV Inhibitors Targeted at the Reverse Transcriptase,” Aids Research and Human Retroviruses, 8(2):119-134 (1992).
Greene, “The Molecular Biology of Human Immunodeficiency Virus Type 1 Infection,” New England Journal of Medicine, 324:308-317 (1991).
Gurevich et al., “Phosphorylation of Indoles with Phosphorus (III) Acid Chlorides,” J. Gen. Chem. USSR (Engl. Transl.), 55(5):1121-1125 (1985).
Haikal, “Synthesis of Guanosine-3′-(5-Bromo-4-Chloroindol-3-YL)-Phosphate (G-3′-BCIP),” Collection of Czechoslovak Chemical Communications, 61(3):427-431 (1996).
Horwitz et al., “Substrates for Cytochemical Demonstration of Enzyme Activity II. Some Dihalo-3-Indolyl Phosphates and Sulfates,” Journal of Medicinal Chemistry, 447 (May 1966).
Horwitz et al., “Substrates for Cytochemical Demonstration of Enzyme Activity V. Thymidine 3′-and 5′-(5-Bromo-4-Chloro-3-Indolyl) Phosphates,” Journal of Medicinal Chemistry, 13(5):1024-1025 (1970).
Jakubik et al., “IDX 12899 anti-HIV-1 Activity and Resistance Profile is Superior to Efavirenz,” Poster 1657 presented at the XVI International HIV Drug Resistance Workshop, Barbados, West Indies (Jun. 12-16, 2007).
Kohlstaedt et al., “Crystal Structure at 3.5 \Anstrom Resolution of HIV-1 Reverse Transcriptase Complexed with an Inhibitor,” Science, 256(5065):1783-1790 (1992).
Mai et al., “Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: Novel Non-Nucleoside Reverse Transcriptase Inhibitors of the S-DABO Series,” J. Med. Chem., 40:1447-1454 (1997).
March et al., “The Synthesis of Ribonucleotide-5′-(5-Iodoindol-3-ol) and (4-Methylcoumarin-7-ol) Esters for the Histochemical Demonstration of Nucleases (1A),” Journal of Heterocyclic Chemistry, 7(4):885-889 (1970).
Mitsuya et al., “Molecular Targets for AIDS Therapy,” Science, 249(4976):1533-1544 (1990).
Pauwels et al., “Potent and Selective Inhibition of HIV-1 Replication in vitro by a Novel Series of TIBO Derivatives,” Nature, 343:470-474 (1990).
Pauwels et al., “Potent and Highly Selective Human Immunodeficiency Virus Type 1 (HIV-1) Inhibition by a Series of α-anilinophenylacetamide Derivates Targeted at HIV-1 Reverse Transcriptase,” PNAS, 90:1711-1715 (1993).
Pontikis et al., “Synthesis and Anti-HIV Activity of Novel N-1 Side Chain-Modified Analogs of 1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT),” J. Med. Chem., 40:1845-1854

Affiliated with

Also associated with

Rating

Enantiomerically pure phosphoindoles as HIV inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Enantiomerically pure phosphoindoles as HIV inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enantiomerically pure phosphoindoles as HIV inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2658365